Fig. 2: Afatinib and crizotinib in combination downregulates IRS-1, RPS6KB1 and RPS6 in vivo and in vitro. | Cell Death & Disease

Fig. 2: Afatinib and crizotinib in combination downregulates IRS-1, RPS6KB1 and RPS6 in vivo and in vitro.

From: Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma

Fig. 2

a Heat map with supervised clustering showing protein expression changes in selected candidates analyzed by RPPA using tumor tissue lysates (n = 20; 5 per group) from A375 xenograft mice treated with vehicle, afatinib and crizotinib alone and in combination for 14 days (5 consecutive days, followed by two days drug off and repetition of same regimen for one more week). b KEGG pathway analysis of candidates significantly altered in a. c Validation of IRS-1, AceCS1, pRPS6, pRPS6KB1 and total RPS6KB1 in xenograft tumor tissues using IF. d, e In vitro validation of selected candidate proteins after 3 h treatment with DMSO, afatinib and crizotinib alone and in combination in seven CMM cell lines (n = 2).

Back to article page